Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.42 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.40 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL601953 | 0.87 | GPBAR1 (0.44) | TP53GPBAR1THRBPOLBGPR119 | |
| SCHEMBL601727 | 0.85 | OPRL1 (0.43) | GPBAR1 | |
| SCHEMBL601054 | 0.79 | GPBAR1 (0.51) | GPBAR1 | |
| SCHEMBL3792941 | 0.78 | GPBAR1 (0.42) | TP53GPBAR1GPR119 | |
| SCHEMBL10227887 | 0.76 | GPBAR1 (0.46) | TP53GPBAR1POLB | |
| SCHEMBL603761 | 0.75 | GPBAR1 (0.52) | GPBAR1 | |
| SCHEMBL602418 | 0.75 | GPBAR1 (0.52) | GPBAR1 | |
| SCHEMBL601541 | 0.74 | GPBAR1 (0.53) | GPBAR1 | |
| SCHEMBL603336 | 0.72 | GPBAR1 (0.46) | GPBAR1 | |
| SCHEMBL602033 | 0.72 | GPBAR1 (0.43) | GPBAR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785488-B2 | Triazole and imidazole derivatives for use as TGR5 agonists in the treatment of diabetes and obesity | EXELIXIS PATENT COMPANY LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120040985-A1 | TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY | EXELIXIS PATENT COMPANY LLC (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040985-A1 | TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY | GPR119, GLP1R, GCGR | TP53 4675/4885CCNT1 3915/4885GPBAR1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.